Recently stock market analysts have updated their consensus ratings on shares of Amgen Inc. (NASDAQ:AMGN). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/29/2016 – Amgen Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 186 price target on the stock.

04/29/2016 – Amgen Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 186 price target on the stock.

03/17/2016 – Amgen Inc. had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 201 price target on the stock.

03/16/2016 – Amgen Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 190 price target on the stock.

03/16/2016 – Amgen Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 191 price target on the stock.

02/25/2016 – Citigroup began new coverage on Amgen Inc. giving the company a “neutral” rating. They now have a USD 165 price target on the stock.

02/22/2016 – Amgen Inc. had its “sell” rating reiterated by analysts at BTIG Research. They now have a USD 135 price target on the stock.

02/11/2016 – Amgen Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 187 price target on the stock.

02/08/2016 – Amgen Inc. had its “buy” rating reiterated by analysts at Argus. They now have a USD 185 price target on the stock.

01/29/2016 – Amgen Inc. had its “neutral” rating reiterated by analysts at JP Morgan. They now have a USD 165 price target on the stock.

01/26/2016 – Amgen Inc. had its “buy” rating reiterated by analysts at UBS. They now have a USD 180 price target on the stock.

01/21/2016 – Amgen Inc. had its “hold” rating reiterated by analysts at Wells Fargo.

01/20/2016 – Credit Suisse began new coverage on Amgen Inc. giving the company a “outperform” rating. They now have a USD 205 price target on the stock.

12/18/2015 – Atlantic Equities began new coverage on Amgen Inc. giving the company a “overweight” rating. They now have a USD 202 price target on the stock.

12/14/2015 – Amgen Inc. was upgraded to “overweight” by analysts at Morgan Stanley. They now have a USD 193 price target on the stock.

Amgen Inc. has a 50 day moving average of 156.18 and a 200 day moving average of 154.54. The stock’s market capitalization is 115.21B, it has a 52-week low of 130.09 and a 52-week high of 181.81.

The share price of the company (NASDAQ:AMGN) was down -0.69% during the last trading session, with a high of 154.45 and the volume of Amgen Inc. shares traded was 3004825.

View other investors thoughts on Amgen Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.